Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Disease Progression 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 3Gemcitabine 3durvalumab 2Cystoscopy 2toripalimab 1pembrolizumab 1enfortumab vedotin 1cemiplimab 1apaziquone 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Standard of Care 1Oncolytic Virotherapy 1Nivolumab 1Magnetic Resonance Imaging 1Interferons 1Imiquimod 1Histamine Antagonists 1Electrocardiography 1Docetaxel 1Diphenhydramine 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Biopsy 1BCG Vaccine 1Acetaminophen 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × Clinical Trials, Phase I as Topic × Genitourinary × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡